Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors. In pre-clinical models, scientists demonstrated that restoring miR-342 levels markedly reduced the spread of cancer cells to distant organs. Furthermore, researchers discovered that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive breast cancers, significantly halted metastatic tumor growth in models exhibiting low miR-342 levels. The findings suggest measuring miR-342 levels could allow doctors to repurpose existing therapeutics to treat high-risk patients.

July marked the second consecutive monthly record for imports by value. Crude oil played a major role in the increase as Japan faced higher energy costs. Crude import volumes rose 5.5% from July 2025, ending three months of year-on-year declines. The value of those crude shipments jumped 87.8% over the same period. Japan remains heavily dependent on imported energy, making changes in oil prices and exchange rates important factors in its merchandise trade figures.

The Democratic Republic of the Congo will receive 70,000 Ervebo Ebola vaccine doses as the Bundibugyo outbreak expands. Congolese authorities reported 5,208 confirmed cases and 2,476 deaths as of Aug. 18. The outbreak now affects 56 health zones across six provinces in the east and northeast. Authorities also listed 1,115 recoveries, while 730 patients remained in isolation or hospital care.

Healthcare shares strengthen market gains
Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

WHO incident manager Thierno Baldé said the three-month timeline depends on securing the resources required for the response. The agency has received about $69.3 million of the $115 million it says it needs, or roughly 60%. Teams added more than 400 treatment beds during the past two weeks. They also deployed 100 additional epidemiologists and more than 500 community health workers for surveillance and contact tracing. The response requires vehicles, ambulances, medical supplies and personnel across a growing affected area. Transmission has reached Bas-Uélé, making it the sixth affected province. As of Aug. 12, Ituri accounted for 85% of confirmed cases and 79% of reported deaths nationwide. Officials said 70% to 80% of new cases had no known link to existing patients. Health teams are expanding surveillance to identify cases faster and transfer patients into treatment centers. Bas-Uélé’s first confirmed case had traveled from Haut-Uélé before symptoms began on Aug. 4.

A magnitude 6.1 earthquake struck off Indonesia’s North Sumatra province on Tuesday, shaking communities across parts of Sumatra. The earthquake occurred at 1:02:23 p.m. western Indonesian time, or 06:02:23 UTC. Official data placed the epicenter in the sea, 147 kilometers southeast of South Nias Regency. The earthquake had a depth of 29 kilometers, with its source beneath waters west of Sumatra. Residents across other parts of Sumatra also reported shaking after the magnitude 6.1 earthquake. The National Disaster Mitigation Agency, or BNPB, said the earthquake had no potential to generate a tsunami. Residents in South Nias felt weak shaking for about three to five seconds. Local disaster offices began monitoring affected areas after the tremor, while the initial national bulletin provided no confirmed casualty or damage figures.